GlassScriptPhysician profile
Agnes L Charles-Torres
NPI 1639166689
$3,489.98
in general payments reported to CMS, 2019-2025
38 companies · $431 in 2025
The $431 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,162 · 2020: $420 · 2021: $783 · 2022: $417 · 2023: $95.84 · 2024: $181 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $509 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $508.71 |
| Education | $198.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $514.21 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $407.84 | 2019-2022 | |
| Genzyme Corporation | $232.47 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $229.73 | 2019-2021 | |
| Astellas Pharma US INC | $206.58 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $192.54 | 2019-2022 | |
| Lilly USA, LLC | $158.85 | 2019-2021 | |
| Amgen INC. | $148.53 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $133.27 | 2019-2021 | |
| Seagen INC. | $125.22 | 2022-2025 | |
| Tersera Therapeutics LLC | $101.88 | 2019 | |
| Incyte Corporation | $100.18 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $100.10 | 2021-2025 | |
| Agios Pharmaceuticals, INC. | $74.67 | 2024 | Pyrukynd |
| Takeda Pharmaceuticals U.S.A., INC. | $64.60 | 2021-2025 | Iclusig |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $60.79 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $55.56 | 2019 | |
| Myriad Genetic Laboratories, INC. | $51.00 | 2021-2023 | Bracanalysis Cdx |
| Blue Earth Diagnostics | $50.78 | 2021-2022 | |
| Celgene Corporation | $47.21 | 2019-2025 | Reblozyl |
| Myovant Sciences INC. | $44.31 | 2021 | |
| Amag Pharmaceuticals, INC. | $43.46 | 2019-2020 | |
| Exelixis INC. | $39.79 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $30.37 | 2023 | Libtayo |
| Janssen Pharmaceuticals, INC | $30.26 | 2019 | |
| Sobi, INC | $28.60 | 2025 | |
| Dova Pharmaceuticals | $24.34 | 2019 | |
| Tesaro, INC. | $23.21 | 2019 | |
| Novo Nordisk INC | $21.06 | 2020 | |
| Epizyme, INC. | $20.47 | 2021 | |
| Daiichi Sankyo INC. | $19.58 | 2024 | Enhertu |
| Mirati Therapeutics, INC. | $18.92 | 2023 | Krazati |
| Sun Pharmaceutical Industries INC. | $18.34 | 2020 | |
| Sumitomo Pharma America, INC. | $17.14 | 2024 | Orgovyx |
| Kite Pharma, INC. | $15.24 | 2020 | |
| Alexion Pharmaceuticals, INC. | $14.92 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $12.04 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Agnes Charles-Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.